Drugs treating conditions related to the central nervous system (CNS) are so far among the most dominant in what looks to be a second consecutive busy year of reviews and approvals for the US FDA's Center for Drug Evaluation and Research (CDER).
Notably among the at least eight novel CNS drugs in CDER's 2018 preliminary pipeline are three anti-calcitonin gene-related peptide (anti-CGRP)...








